FDA officials summarise the agency's advance:
This article was originally published in Clinica
Executive Summary
The investigational device exemptions granted by the FDA within 30 days of submission have more than doubled to 73 in the past three years. The backlog of PMA supplements, which authorise companies to make significant changes to high-risk devices, has been reduced by a factor of 10 in the same period. The backlog of 510(k) submissions, for which the agency must determine whether the technology described has substantial equivalence to existing products, is now one a month at most, compared with 2,000 in 1993.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.